Market Research Reports

  Global Phosphoramidite Market: Industry Overview The global  phosphoramidite market   is projected to reach $2,062.9 million by 2032 from $900.3 million in 2021, at a CAGR of 7.78% during the forecast period 2022-2032. The market growth can be ascribed to the rising demand for oligonucleotides, growing synthetic biology market, increasing partnerships and collaborations, continuous investment for research and development activities by private and public firms, and growing prevalence of several diseases creating an urgent need for novel therapeutic treatments.   Recent Developments in the Global Phosphoramidite Market •    In August 2019, the company acquired 75% ordinary capital of the parent company of Toronto Research Chemicals Inc., i.e., Biomed Pharmaceutical Limited. •    In July 2022, TriLink BioTechnologies expanded its RD leadership team's responsibility for leading the company’s scientific direction and research and development strategy. •    In May 2022, TriLink BioTech

  One of the primary objectives of molecular biology research is to identify the structure of proteins. Protein complex analysis requires a thorough research of proteins' structure and function because they are found in complicated biological samples. The structure of protein complexes can be ascertained using contemporary protein complex analysis methods. Many studies are currently being conducted employing cryo-electron microscopy (EM), small angle X-ray scattering (SAXS), nuclear magnetic resonance (NMR) spectroscopy, and X-ray crystallography to describe and understand molecular structures and molecular recognition mechanisms. Equipment for 3D protein structure analysis is available from reputable manufacturers including Bruker Corporation, JEOL Ltd., and Spectris plc depending on what is required. These tools can meet the laboratory's throughput requirements. In 2021, the global  3D protein structure analysis market  was valued at $1,017.2 million, and it is expected to re

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has been foun

  The growth of the precision medicine market over the last few years has been monumental. New technologies are rapidly being introduced, expanding the arsenal of tools accessible to support the development and adoption of precision medicine solutions over “one-size-fits-all” therapies. Advancements in gene therapies, cell therapies, molecular biomarker analysis, and companion diagnostics have the potential to transform medicine and increase the ability to treat and cure several intractable diseases. Advances in sequencing technologies and non-invasive diagnostics, such as liquid biopsy and non-invasive prenatal testing (NIPT), have facilitated the acquisition of real-time data and gained interest for their usage in acquiring the data by exhibiting the biology of tumors and metastatic tissues. The  Middle East precision medicine market  was estimated to be at $3,942.6 million in 2021, which is expected to grow with a CAGR of 7.37% and reach $8,620.0 million by 2032. The Middle East pre